EXEL · Exelixis, Inc. · Webcasts, Transcripts & Audio
$64.63
-1.20 (-1.82%)
At close · Nov 20
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$15.77B
Shares
244.01M
Volume · Nov 20
2.19M
Avg daily vol (3M)
2.44M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Exelixis, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Exelixis, Inc. (EXEL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-18
Exelixis, Inc. (EXEL) November 18, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Exelixis, Inc. (EXEL) November 17, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-11
Exelixis, Inc. (EXEL) November 11, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-10
Exelixis, Inc. (EXEL) November 10, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-29
Exelixis, Inc. (EXEL) Q3 2026 Earnings Call Transcript
Confident tone
Cabo commercial growth
ZANSA franchise expansion
Colorectal cancer launch opportunity
Revenue
$658.70M
▲ 10.2% YoY Diluted EPS
$0.85
▲ 23.2% YoY Gross margin
96.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-15
Exelixis, Inc. (EXEL) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-09
Exelixis, Inc. (EXEL) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-08
Exelixis, Inc. (EXEL) September 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Exelixis, Inc. (EXEL) Q2 2026 Earnings Call Transcript
Positive tone
NET indication ramp
Cabozantinib (Cabo) commercial performance
2026 financial guidance revision
Revenue
$628.69M
▲ 10.6% YoY Diluted EPS
$0.82
▲ 26.2% YoY Gross margin
96.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Exelixis, Inc. (EXEL) June 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Exelixis, Inc. (EXEL) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-27
Exelixis, Inc. (EXEL) May 27, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-19
Exelixis, Inc. (EXEL) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Exelixis, Inc. (EXEL) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call Transcript
Confident tone
ZANSA in renal cell carcinoma franchise
Zanzalintinib (ZANSA) CRC launch and Stellar 303
ZANSA in neuroendocrine tumors and meningioma
Revenue
$610.81M
▲ 10% YoY Diluted EPS
$0.79
▲ 43.6% YoY Gross margin
96.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-10
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
Confident tone
Zanzalintinib (ZANZA) franchise opportunity
Cabozantinib (CABOMETYX) franchise performance
Pipeline / R&D strategy
Revenue
$598.66M*
▲ 5.6% YoY Gross margin
95.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript
Confident tone
Zanzalintinib pipeline and STELLAR-303 CRC results
NET indication launch
CRC market dynamics and competition
Revenue
$597.75M
▲ 10.8% YoY Diluted EPS
$0.69
▲ 72.5% YoY Gross margin
96.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-28
Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript
Confident tone
STELLAR-303 zanzalintinib in CRC
Early-stage pipeline advancement
Gross-to-net dynamics and 340B
Revenue
$568.26M
▼ 10.8% YoY Diluted EPS
$0.65
▼ 15.6% YoY Gross margin
96.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript
Confident tone
CABOMETYX commercial performance
NET launch
Early-stage pipeline and INDs
Revenue
$555.45M
▲ 30.6% YoY Diluted EPS
$0.55
▲ 358.3% YoY Gross margin
96.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Date not confirmed
Exelixis, Inc. (EXEL) Q4 2024 Earnings Call Transcript
Confident tone
Zanzalintinib pivotal trials
Cabozantinib commercial performance
STELLAR-303 colorectal cancer data and trial design
Revenue
$566.75M*
▲ 18.2% YoY Gross margin
96.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript
Confident tone
Cabozantinib (CABOMETYX) franchise performance
Early-stage pipeline (XL309, XB010, XL495)
Merck collaboration on Zanza
Revenue
$539.54M
▲ 14.3% YoY Diluted EPS
$0.40
Gross margin
96.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Exelixis, Inc. (EXEL) Q2 2024 Earnings Call Transcript
Confident tone
CABINET sNDA and neuroendocrine tumors (NET) launch
Cabozantinib commercial performance and RCC leadership
Discovery and IND-enabling programs
Revenue
$637.18M
▲ 35.6% YoY Diluted EPS
$0.77
▲ 208% YoY Gross margin
97.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript
Positive tone
Zanzalintinib development
Cabozantinib (CABOMETYX) commercial performance
Early-stage pipeline / discovery
Revenue
$425.23M
▲ 4% YoY Diluted EPS
$0.12
▲ 0% YoY Gross margin
95.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Date not confirmed
Exelixis, Inc. (EXEL) Q4 2023 Earnings Call Transcript
Revenue
$479.65M*
▲ 13.1% YoY Gross margin
95.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-01
Exelixis, Inc. (EXEL) Q3 2023 Earnings Call Transcript
Revenue
$471.92M
▲ 14.6% YoY Diluted EPS
$0.00
▼ 100% YoY Gross margin
96.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Exelixis, Inc. (EXEL) Q2 2023 Earnings Call Transcript
Revenue
$469.85M
▲ 12% YoY Diluted EPS
$0.25
▲ 13.6% YoY Gross margin
96.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Exelixis, Inc. (EXEL) Q1 2023 Earnings Call Transcript
Revenue
$408.79M
▲ 14.8% YoY Diluted EPS
$0.12
▼ 42.9% YoY Gross margin
96.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-31
Date not confirmed
Exelixis, Inc. (EXEL) Q4 2022 Earnings Call Transcript
Revenue
$423.92M*
▼ 6% YoY Gross margin
96.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Exelixis, Inc. (EXEL) Q3 2022 Earnings Call Transcript
Revenue
$411.74M
▲ 25.4% YoY Diluted EPS
$0.23
▲ 91.7% YoY Gross margin
96.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Exelixis, Inc. (EXEL) Q2 2022 Earnings Call Transcript
Revenue
$419.43M
▲ 8.9% YoY Diluted EPS
$0.22
▼ 26.7% YoY Gross margin
96.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Exelixis, Inc. (EXEL) Q1 2022 Earnings Call Transcript
Revenue
$355.98M
▲ 31.7% YoY Diluted EPS
$0.21
Gross margin
96.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Date not confirmed
Exelixis, Inc. (EXEL) Q4 2021 Earnings Call Transcript
Revenue
$451.14M*
▲ 67.1% YoY Gross margin
97.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Exelixis, Inc. (EXEL) Q3 2021 Earnings Call Transcript
Revenue
$328.42M
▲ 42.1% YoY Diluted EPS
$0.12
Gross margin
96.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Exelixis, Inc. (EXEL) Q2 2021 Earnings Call Transcript
Revenue
$385.18M
▲ 48.4% YoY Diluted EPS
$0.30
▲ 42.9% YoY Gross margin
96.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Exelixis, Inc. (EXEL) Q1 2021 Earnings Call Transcript
Revenue
$270.23M
▲ 19.1% YoY Diluted EPS
$0.00
▼ 100% YoY Gross margin
95.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Date not confirmed
Exelixis, Inc. (EXEL) Q4 2020 Earnings Call Transcript
Revenue
$270.05M
▲ 12.4% YoY Diluted EPS
$0.09
▼ 59.1% YoY Gross margin
70.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Exelixis, Inc. (EXEL) Q3 2020 Earnings Call Transcript
Revenue
$231.09M
▼ 14.9% YoY Diluted EPS
$-0.10
▼ 132.3% YoY Gross margin
69.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Exelixis, Inc. (EXEL) Q2 2020 Earnings Call Transcript
Revenue
$259.48M
▲ 8% YoY Diluted EPS
$0.21
▼ 16% YoY Gross margin
65.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Exelixis, Inc. (EXEL) Q1 2020 Earnings Call Transcript
Revenue
$226.91M
▲ 5.3% YoY Diluted EPS
$0.15
▼ 37.5% YoY Gross margin
81.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–39 of 39 webcasts
Key facts
CIK
939767
CUSIP
30161Q104
13F (30d)
716 filings
661 filers
Visit website
Investor relations